Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia

Samer A. Srour, Denái R. Milton, Asad Bashey, Amado Karduss-Urueta, Monzr M. Al Malki, Rizwan Romee, Scott Solomon, Auayporn Nademanee, Stacey Brown, Michael Slade, Rosendo Perez, Gabriela Rondon, Stephan J. Forman, Richard E. Champlin, Partow Kebriaei, Stefan O. Ciurea

Research output: Contribution to journalArticlepeer-review

46 Scopus citations


Haploidentical transplantation performed with post-transplantation cyclophosphamide (PTCy)–based graft-versus-host disease (GVHD) prophylaxis has been associated with favorable outcomes for patients with acute myeloid leukemia and lymphomas. However, it remains unclear if such approach is effective for patients with acute lymphoblastic leukemia (ALL). We analyzed outcomes of 109 consecutively treated ALL patients 18 years of age and older at 5 institutions. The median age was 32 years and the median follow-up for survivors was 13 months. Thirty-two patients were in first complete remission (CR1), while the rest were beyond CR1. Neutrophil engraftment occurred in 95% of the patients. The cumulative incidences of grades II to IV and III and IV acute GVHD at day 100 after transplantation were 32% and 11%, respectively, whereas chronic GVHD, nonrelapse mortality, relapse rate, and disease-free survival (DFS) at 1 year after transplantation were 32%, 21%, 27%, and 51%, respectively. Patients in CR1 had 52% DFS at 3 years. These results suggest that haploidentical transplants performed with PTCy-based GVHD prophylaxis provide a very suitable alternative to HLA-matched transplantations for patients with ALL.

Original languageEnglish
Pages (from-to)318-324
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Issue number2
StatePublished - Feb 1 2017


  • Acute lymphoblastic leukemia
  • Haploidentical transplantation


Dive into the research topics of 'Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia'. Together they form a unique fingerprint.

Cite this